Company Badge
USPTO Data Jan 1 1976 - Oct 13 2026
4 Patents
#130 in Oslo
#413 in Norway
Ultimovacs as
Forward Citations = 6
4 inventors:
Ultimovacs as
EPO Patents = 1
Forward Citations = 6
Loading Chart...
Loading Chart...
4 inventors (with patents filed for the assignee):
Gustav Gaudernack (4 out of 21 patents)
Else Marit Inderberg Suso (3 out of 4 patents)
Anne-Marie Rasmussen (3 out of 4 patents)
4. Audun Tornes (1 out of 2 patents)
4 patents:
Company Overview
Ultimovacs is a clinical-stage pharmaceutical company developing novel immunotherapies for the treatment of cancer. Their lead product candidate, UV1, is a therapeutic cancer vaccine designed to induce a specific T cell response against tumors. Ultimovacs' mission is to improve the lives of cancer patients by harnessing the power of the immune system to fight cancer.
Profile summary synthesized from public USPTO records and patent filings.
IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Ultimovacs as. Retrieved from https://idiyas.com/company/ultimovacs-as
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
1 patent (EPO):
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]